Kalaris Therapeutics (KLRS) AI Stock Analysis

• Market Cap: $42.68M
• Dividend Yield: N/A
• Average Volume (3M): 47.87K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.16
• Revenue Growth: N/A
• EPS Growth: 72.12%
• Country: US
• Employees: 14
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -11.75
• Shares Outstanding: 18,702,417
• 10 Day Avg. Volume: 62,231
• 30 Day Avg. Volume: 47,869
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: -1.60
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 7.82
• 1Y Price Target: $11.50
• Price Target Upside: 345.74% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3

• Rating: 28 Underperform
• Price Target: ―

AlloVir's stock is heavily impacted by its financial performance challenges, including consistent net losses and negative cash flow. Technical analysis also indicates a bearish trend, with prices below key moving averages and weak momentum indicators. The negative P/E ratio and absence of dividend yield further highlight valuation concerns, making it a less attractive investment at this time.

Positive Factors

Financial Stability

The company ended the first quarter of 2025 with $101 million in cash, providing a financial runway for future developments.

Market Potential

The global branded anti-VEGF market is still worth more than $15 billion and is growing at a steady pace, illustrating the potential value of a therapy that meaningfully extends treatment intervals.

Product Differentiation

TH103 is a fully humanized recombinant anti-VEGF fusion protein designed to offer greater affinity for VEGF and longer residence time in the eye compared to Eylea.

Negative Factors

Clinical Data Concerns

The preclinical data for the company's anti-VEGF, TH103, are not sufficient evidence to provide what the differentiation would be compared to standard of care in retinal diseases.

Competitive Market

There are several other players aiming to extend the treatment interval in wet AMD, so this space may become competitive.

Lack of Human Data

TH103 is currently in early-stage clinical development, and there is not much human data yet.

Kalaris Therapeutics Business Overview & Revenue Model

Company Description

AlloVir, Inc. (ALVR) is a biotechnology company focused on developing allogeneic, off-the-shelf virus-specific T cell therapies designed to combat and prevent viral infections in immunocompromised patients. Operating in the healthcare and life sciences sector, AlloVir's core products include investigational therapies for treating viral infections such as cytomegalovirus, adenovirus, and BK virus, primarily targeting patients undergoing hematopoietic stem cell transplantation and other vulnerable populations.

How the Company Makes Money

AlloVir makes money primarily through the development and commercialization of its proprietary T cell therapies. The company's revenue model focuses on the successful progression of its clinical trials and eventual regulatory approval, allowing for the marketing and sale of its therapies. Key revenue streams include potential milestone payments and royalties from partnerships with pharmaceutical companies and healthcare providers. AlloVir's earnings are significantly influenced by its ability to advance its clinical pipeline and secure strategic collaborations to support its research and development efforts.

Kalaris Therapeutics Financial Statement Overview

Summary

AlloVir faces significant financial challenges typical of biotech firms in the development phase. The absence of revenue underscores reliance on external funding to sustain operations. While the company has managed to maintain a strong cash position, the ongoing net losses and negative cash flows highlight the need for breakthroughs in product development or revenue generation to achieve financial sustainability.

Income Statement

AlloVir's income statement shows consistent challenges with revenue generation, as the company reported no revenue in the latest periods. This has led to substantial net losses, reflecting the ongoing high costs without offsetting income. The company’s EBIT and EBITDA margins are negative, indicating a significant challenge in managing operational expenses efficiently.

Balance Sheet

The balance sheet reflects a relatively strong equity position with no debt as of the latest report, which is positive. However, the consistent net losses have eroded equity over time. The company’s equity ratio is relatively healthy, indicating a strong reliance on equity financing rather than debt, which reduces financial risk in the near term.

Cash Flow

AlloVir's cash flow statement highlights significant operational cash outflows, reflecting the ongoing operational costs without revenue support. The free cash flow is negative, indicating reliance on external financing or cash reserves for sustainability. However, cash flow from financing activities has helped bolster cash reserves.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	165.00K
Gross Profit	0.00	0.00	-1.12M	-73.00K	165.00K
EBITDA	-14.01M	-15.25M	-169.84M	-69.71M	-26.68M
Net Income	-14.70M	-15.48M	-171.96M	-68.38M	-21.77M
Balance Sheet
Total Assets	3.33M	3.90M	286.59M	370.82M	139.42M
Cash, Cash Equivalents and Short-Term Investments	3.17M	3.06M	248.12M	356.32M	126.08M
Total Debt	0.00	3.25M	30.07M	8.69M	11.76M
Total Liabilities	48.35M	34.17M	61.33M	17.76M	190.93M
Stockholders Equity	-45.02M	-30.27M	225.27M	353.06M	-51.50M
Cash Flow
Free Cash Flow	-14.13M	-9.78M	-106.34M	-61.05M	-20.49M
Operating Cash Flow	-14.13M	-9.78M	-106.32M	-60.81M	-20.16M
Investing Cash Flow	0.00	0.00	185.98M	-169.50M	-64.64M
Financing Cash Flow	14.24M	12.78M	232.00K	291.98M	120.92M

Kalaris Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.58
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KLRS, the sentiment is Negative. The current price of 2.58 is below the 20-day moving average (MA) of 2.60, below the 50-day MA of 2.70, and below the 200-day MA of 8.55, indicating a bearish trend. The MACD of -0.03 indicates Negative momentum. The RSI at 45.05 is Neutral, neither overbought nor oversold. The STOCH value of 41.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for KLRS.

Kalaris Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CLLS	61 Neutral	$194.31M	―	-48.26%	―	825.97%	38.32%
Sector *	51 Neutral	$7.38B	0.52	-67.26%	2.36%	16.67%	-0.20%
NKTR	50 Neutral	$397.23M	―	-189.46%	―	-3.24%	31.00%
CHRS	42 Neutral	$101.77M	5.55	0.51%	―	-34.58%	-62.19%
MCRB	42 Neutral	$122.17M	―	-3758.21%	―	-100.00%	-7.66%
KOD	35 Underperform	$350.88M	―	-108.92%	―	―	32.58%
KLRS	28 Underperform	$42.68M	―	-41.96%	―	―	72.12%

Kalaris Therapeutics Corporate Events

Kalaris Therapeutics Amends Executive Employment Agreements

On April 10, 2025, Kalaris Therapeutics, Inc. finalized an employment agreement with Andrew Oxtoby, continuing his role as President and CEO. The agreement includes a base salary, potential performance bonuses, and severance terms in case of termination, especially around changes in company control. Similarly, on April 15, 2025, Kalaris amended the offer letter for Brett Hagen, the Senior Vice President and Chief Accounting Officer, to include severance benefits. These agreements aim to secure leadership stability and provide financial assurance to key executives, potentially impacting the company’s strategic direction and stakeholder confidence.

Spark’s Take on KLRS Stock

According to Spark, TipRanks’ AI Analyst, KLRS is a Neutral.

AlloVir’s overall stock score reflects its challenging financial situation, characterized by no revenue and ongoing losses, balanced by a strong equity position with no debt. Technical analysis shows short-term positive momentum, while valuation metrics highlight the speculative nature of the stock. The recent merger with Kalaris Therapeutics provides a significant positive catalyst, offering financial support and strategic development opportunities.

To see Spark’s full report on KLRS stock, click here.

Kalaris Therapeutics Appoints Leone Patterson to Board

On April 3, 2025, Kalaris Therapeutics, Inc. announced the election of Leone Patterson to its Board of Directors as a Class III director, with her term set to expire at the 2026 annual meeting of stockholders. Ms. Patterson was also appointed as Chair of the Audit Committee, joining Anthony Adamis, M.D., and Morana Jovan-Embiricos, Ph.D. The company plans to implement a new Non-Employee Director Compensation Program, under which Ms. Patterson will receive compensation for her board and committee service. Additionally, she will enter into an indemnification agreement with the company, ensuring protection against certain legal expenses related to her directorial role.